[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2]SAIKA T,MIURA N,FUKUMOTO T,et al.Role of robot-assisted radical prostatectomy in locally advanced prostate cancer[J].Int J Urol,2018,25(1):30-35.
[3]CAI L,TSAI YH,WANG P,et al.ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer[J].Mol Cell,2018,72(2):341-354.
[4]HAHN AW,GILL DM,POOLE A,et al.Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone(AA) in new-onset metastatic castration-resistant prostate cancer(mCRPC)[J].Mol Cancer Ther,2019,18(3):726-729.
[5]CHOI SY,XUE H,WU R,et al.The MCT4 gene:A novel,potential target for therapy of advanced prostate cancer[J].Clin Cancer Res,2016,22(11):2721-2733.
[6]TORO-DOMINGUEZ D,MARTORELL-MARUGAN J,LOPEZ-DOMINGUEZ R,et al.ImaGEO:integrative gene expression meta-analysis from GEO database[J].Bioinformatics,2019,35(5):880-882.
[7]林艳端,申锷,胡兵.三种常见的前列腺癌细胞系LNCaP、PC3和DU145的生物学特性[J].中华临床医师杂志,2013,7(11):4980-4982.
LIN YD,SHEN E,HU B.Biological characteristics of three common prostate cancer cell lines:LNCaP,PC3 and DU145[J].Chinese Journal of Clinicians,2013,7(11):4980-4982.
[8]HUSSON O,VAN STEENBERGEN LN,KOLDEWIJN EL,et al.Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis[J].BJU Int,2014,114(5):691-697.
[9]CENTER MM,JEMAL A,LORTET-TIEULENT J,et al.International variation in prostate cancer incidence and mortality rates[J].Eur Urol,2012,61(6):1079-1092.
[10]GE R,WANG Z,MONTIRONI R,et al.Epigenetic modulations and lineage plasticity in advanced prostate cancer[J].Ann Oncol,2020,31(4):470-479.
[11]TODENHOFER T,SEILER R,STEWART C,et al.Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder cancer[J].Mol Cancer Ther,2018,17(12):2746-2755.
[12]ANDERSEN S,SOLSTAD O,MOI L,et al.Organized metabolic crime in prostate cancer:The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure[J].Urol Oncol,2015,33(8):338-339.
[13]MARTINEZ-OUTSCHOORN UE,LISANTI MP,SOTGIA F.Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells,fueling tumor growth[J].Semin Cancer Biol,2014,25:47-60.
[14]FIASCHI T,MARINI A,GIANNONI E,et al.Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay[J].Cancer Res,2012,72(19):5130-5140.
[15]SRIRAM R,VAN CRIEKINGE M,DELOS SJ,et al.Elevated tumor lactate and efflux in high-grade prostate cancer demonstrated by hyperpolarized(13)C magnetic resonance spectroscopy of prostate tissue slice cultures[J].Cancers(Basel),2020,12(3):537.
[16]BOK R,LEE J,SRIRAM R,et al.The role of lactate metabolism in prostate cancer progression and metastases revealed by dual-agent hyperpolarized(13)C MRSI[J].Cancers(Basel),2019,11(2):257.
[17]CHOI S,ETTINGER SL,LIN D,et al.Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer[J].Cancer Med,2018,7(7):3385-3392.
[18]CHO B,LEE H,JEONG S,et al.Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma[J].Biochem Biophys Res Commun,2003,307(1):52-63.
[19]KWON Y,KIM Y,JUNG HS,et al.Role of HDAC3-miRNA-CAGE network in anti-cancer drug-resistance[J].Int J Mol Sci,2018,20(1):51.
[20]KIM Y,YEON M,JEOUNG D.DDX53 regulates cancer stem cell-like properties by binding to SOX-2[J].Mol Cells,2017,40(5):322-330.
[21]PARK SY,KIM WJ,BYUN JH,et al.Role of DDX53 in taxol-resistance of cervix cancer cells in vitro[J].Biochem Biophys Res Commun,2018,506(3):641-647.